Physician profile
Brian N King
NPI 1841493913
$3,381.90
in general payments reported to CMS, 2019-2025
32 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $357 · 2021: $386 · 2022: $313 · 2023: $879 · 2024: $518 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $706.61 | 2019-2025 | Eluvia, Enroute Transcarotid Neuroprotection System, Ranger |
| Endologix LLC | $600.26 | 2023-2025 | Alto Abdominal Stent Graft System, Afx2 Bifurcated Endograft System |
| Medtronic, INC. | $465.02 | 2021-2025 | Abre, Concertotm, Venaseal |
| E.R. Squibb & Sons, L.L.C. | $131.30 | 2019-2025 | Eliquis |
| W. L. Gore & Associates, INC. | $131.17 | 2021 | |
| Philips North America LLC | $99.35 | 2022-2023 | |
| Lemaitre Vascular, INC. | $96.73 | 2020-2025 | Syntel Embolectomy Catheter (Spring Tip), Artegraft Vascular Graft, Hydro Lemaitre Valvulotome |
| Abbott Laboratories | $89.45 | 2022-2025 | Esprit, Jeti Peripheral Catheter |
| Pfizer INC. | $88.52 | 2019-2022 | |
| Medtronic Vascular, INC. | $78.94 | 2019-2020 | |
| Inari Medical, INC. | $73.10 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $69.67 | 2020-2024 | Xarelto |
| Silk Road Medical, INC. | $64.55 | 2019 | |
| Lilly USA, LLC | $62.75 | 2019-2021 | |
| Shockwave Medical, INC | $60.73 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| My01 INC. | $60.51 | 2023 | My01 Continuous Compartmental Pressure Monitor |
| Inspire Medical Systems, INC. | $59.25 | 2024-2025 | Inspire |
| Smith+Nephew, INC. | $55.48 | 2022 | |
| Penumbra, INC. | $49.87 | 2021-2024 | Penumbra System |
| Angiodynamics, INC. | $44.44 | 2019-2023 | Auryon Laser System 100-120 Vac |
| Solventum Corporation | $41.76 | 2024-2025 | Promogran Prisma, Prevena, 3m Coban |
| Stryker Corporation | $40.76 | 2025 | Artix Mt |
| Misonix INC | $31.19 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.80 | 2024 | Ultomiris |
| Cordis US Corp. | $23.90 | 2024 | Mynx Control |
| Organogenesis INC. | $22.24 | 2021 | |
| Portola Pharmaceuticals, LLC | $21.47 | 2019 | |
| Siemens Medical Solutions USA, INC. | $19.83 | 2020 | |
| Terumo Medical Corporation | $19.83 | 2024 | Azur Cx Detachable |
| Kci USA, INC. | $19.71 | 2023 | V.A.C. Dermatac, Kerramax Care, Activ.A.C. |
| Tactile Systems Technology INC | $15.48 | 2019 | |
| Bard Peripheral Vascular, INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.